Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTCQX: PYNKF) has joined the Industry Relations Council of the American Society of Breast Surgeons, a move that could help strengthen its standing in the breast cancer care community at a crucial moment in the evolution of breast surgery. The company, headquartered in both Toronto and Dallas, is betting on the power of close dialogue with the surgeon community and its leaders to help bring advanced imaging technology into wider clinical practice.
By joining the Industry Relations Council, Perimeter aligns itself with a who’s-who of companies involved in breast disease diagnosis, treatment, and care. The Council exists as a bridge between innovators in the medical industry and the leading organization for general surgeons treating breast disease, the American Society of Breast Surgeons. For Perimeter, this means not only a seat at the table but also a platform to help shape best practices, share clinical evidence, and connect with professionals who drive daily decisions affecting breast cancer patients.
The timing is noteworthy. New techniques and technologies have been driving rapid advancement in breast care. According to Dr. Michael Berry, the current president of the Society, successful collaboration between surgeons and industry partners is essential to delivering high-quality and cost-effective care to patients. Companies like Perimeter, with offerings that promise to bring better precision and efficiency to surgery, are particularly welcome as key conversations unfold regarding the standards and tools that will define the next few years.
Perimeter’s primary commercial technology, the S-Series Optical Coherence Tomography (OCT) system, is currently cleared by the U.S. Food and Drug Administration and is offered in healthcare settings across the United States. This system allows real-time, high-resolution visualization of tissues at the cellular level after they are removed during surgery. For surgeons, that means a better shot at assessing whether all cancer has been removed before the patient leaves the operating room, potentially reducing the need for repeat procedures.
However, Perimeter is not solely resting on the success of its S-Series technology. The company is looking to the future with its B-Series OCT, which incorporates advanced artificial intelligence. This next-generation product recently completed a pivotal clinical trial. Notably, its development has received significant outside validation and support, including a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas. While the B-Series is still under U.S. Food and Drug Administration review and is not yet cleared for sale, the company sees its integration of AI as the next big leap in real-time margin assessment and cancer surgery guidance. CEO Adrian Mendes emphasized that participating in the Industry Relations Council is about more than networking; it’s a strategic opportunity to engage in conversations that could influence not only Perimeter’s trajectory but also surgical practice at large.
As of now, the S-Series OCT is FDA-cleared for general use, but specific claims regarding its utility in breast tissue, margin evaluation, or reducing the need for further surgeries have not been fully established. The next year will likely be pivotal for Perimeter as it awaits regulatory outcomes and leverages its new relationships within the breast surgery clinical community.
For a company whose stock ticker “PINK” draws direct inspiration from the powerful symbolism of the pink ribbon, this isn’t just about cold technology. It’s a reminder that advances in imaging and AI can place new tools in the hands of skilled surgeons, with tangible results for patients facing breast cancer.
